2. Signaling Pathways
  3. GPCR/G Protein
  4. P2Y Receptor

P2Y Receptor

P2Y Receptor

Related Products

PDF 0.7 MB

P2Y receptors are a class of G protein-coupled receptors (GPCRs) activated by extracellular nucleotides (ATP, UTP, and UDP). There are eight mammalian P2Y receptor subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14). The P2Y receptors are expressed in various cell types and play important roles in physiology and pathophysiology including inflammatory responses and neuropathic pain.

The P2Y family can be further divided into a subfamily of five P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11Rs (“P2Y1-like”) that stimulate phospholipase C (PLC) through Gq protein and a second subfamily of P2Y12, P2Y13, and P2Y14Rs (“P2Y12-like”) that inhibit adenylate cyclase through Gi protein. Other effector pathways have been documented, such as coupling of the P2Y11R to Gs as well as to Gq in some cells to induce stimulation of cyclic AMP production.

P2Y Receptor Isoform Specific Products:

P2Y Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-RS09928
    P2RY2 Human Pre-designed siRNA Set A
    		Inhibitor

    P2RY2 Human Pre-designed siRNA Set A contains three designed siRNAs for P2RY2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    P2RY2 Human Pre-designed siRNA Set A
  • HY-W686186
    Prasugrel hydroxy thiolactone
    		Control
    Prasugrel hydroxy thiolactone (compound M18) is a metabolite of Prasugrel (HY-15284). Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits Adenosine 5'-diphosphate (ADP, HY-W010918)-induced platelet aggregation.
    Prasugrel hydroxy thiolactone
  • HY-RS09915
    P2ry1 Mouse Pre-designed siRNA Set A
    		Inhibitor

    P2ry1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for P2ry1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    P2ry1 Mouse Pre-designed siRNA Set A
  • HY-108664
    MRS2957
    		Agonist
    MRS2957 is a P2Y6 receptor agonist that activates AMPK in pancreatic β-cells, promoting insulin secretion and reducing apoptosis, thereby holding potential as a therapeutic target for type 2 diabetes.
    MRS2957
  • HY-172181
    NSC380324
    		Antagonist
    NSC380324 is a P2Y12 receptor antagonist, possessing antiplatelet activity, and can be utilized in research on atherosclerotic cardiovascular diseases.
    NSC380324
  • HY-150524
    UDP-Galactose
    		Agonist
    UDP-Galactose is a monosaccharide involved in nucleotide sugar metabolism. UDP-Galactose and its derivatives act as a natural agonist for Gi protein-conjugated P2Y14 receptors in the immune system (IC50=0.67 μM, hP2Y14).
    UDP-Galactose
  • HY-15284R
    Prasugrel (Standard)
    		Inhibitor
    Prasugrel (Standard) is the analytical standard of Prasugrel. This product is intended for research and analytical applications. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
    Prasugrel (Standard)
  • HY-137610A
    TNP-ATP tetrasodium
    		Antagonist
    TNP-ATP is an antagonist of purinergic P2Y1, P2X3, and P2X2/3 receptors (IC50 = 6, 0.9, and 7 nM, respectively, in HEK293 cells expressing human receptors). TNP-ATP reduces acetate-induced calcium flux in 1321N1 cells expressing P2X3 and P2X2/3 receptors (IC50 = 100 and 62 nM, respectively). TNP-ATP dose-dependently attenuates acetate-induced abdominal contractions in a mouse visceral pain model (ED50 = 6.35 µmol/kg)[1][2].
    TNP-ATP tetrasodium
  • HY-15284S3
    Prasugrel-13C6
    		Inhibitor
    Prasugrel-13C6 is a deuterated labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
    Prasugrel-<sup>13</sup>C<sub>6</sub>
  • HY-RS09919
    P2RY12 Human Pre-designed siRNA Set A
    		Inhibitor

    P2RY12 Human Pre-designed siRNA Set A contains three designed siRNAs for P2RY12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    P2RY12 Human Pre-designed siRNA Set A
  • HY-110089
    mrs 4062 TEA
    		Agonist
    mrs 4062 (TEA) is a selective P2Y4 receptor agonist with an EC50 of 23 nM. mrs 4062 (TEA) has EC50s of 640 nM and 740 nM for P2Y2 and P2Y6, respectively.
    mrs 4062 TEA
  • HY-RS09930
    P2ry2 Rat Pre-designed siRNA Set A
    		Inhibitor

    P2ry2 Rat Pre-designed siRNA Set A contains three designed siRNAs for P2ry2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    P2ry2 Rat Pre-designed siRNA Set A
  • HY-RS09932
    P2ry4 Mouse Pre-designed siRNA Set A
    		Inhibitor

    P2ry4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for P2ry4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    P2ry4 Mouse Pre-designed siRNA Set A
  • HY-137616C
    Rp-dUTPαS tetrasodium
    		Agonist
    Rp-dUTPαS (tetrasodium) is an isomer of the sulfur-containing nucleoride dUTP-α-S and an agonist of the purinergic P2Y2 receptor. Rp-dUTPαS (tetrasodium) selectively induces inositol phosphate accumulation in P2Y2-expressing 1321N1 cells with an EC50 of 12.5 μM.
    Rp-dUTPαS tetrasodium
  • HY-167855
    MRS4833
    		Antagonist
    MRS4833 (compound 15) is an orally active, potent, competitive P2Y14R antagonist with an of IC50 of 5.92 nM for hP2Y14R and an IC50 of 4.8 nM for mP2Y14R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model.
    MRS4833
  • HY-107867S2
    Clopidogrel-13C,d3 sulfate
    Clopidogrel-13C,d3 sulfate is the deuterium and 13C-labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects.
    Clopidogrel-<sup>13</sup>C,d<sub>3</sub> sulfate
  • HY-113359AS1
    Uridine 5'-diphosphate-13C9 dilithium
    		Agonist
    Uridine 5'-diphosphate-13C9 dilithium is 13C-labeled Uridine 5'-diphosphate (HY-113359). Uridine 5'-diphosphate is a P2Y6 receptor agonist with an EC50 of 0.013 μM for human P2Y6 receptor.
    Uridine 5'-diphosphate-<sup>13</sup>C<sub>9</sub> dilithium
  • HY-113359
    Uridine 5'-diphosphate
    		Agonist
    Uridine 5'-diphosphate is a P2Y6 receptor agonist with an EC50 of 0.013 μM for human P2Y6 receptor.
    Uridine 5'-diphosphate
  • HY-103064
    2-Methylthio-AMP sodium
    		Antagonist
    2-Methylthio-AMP sodium is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP sodium is an inhibitor of ADP-dependent platelet aggregation.
    2-Methylthio-AMP sodium
  • HY-116295A
    MRS2690 disodium
    		Agonist
    MRS2690 disodium is a selective P2Y14 receptor agonist. MRS2690 disodium inhibits adenylyl cyclase activity, thereby reducing intracellular cAMP levels and mediating concentration-dependent vasoconstriction of porcine coronary arteries. MRS2690 disodium induces intracellular calcium mobilization, activates P38 and stimulates [35S]GTPγS binding to RBL-2H3 cell membranes. MRS2690 enhances antigen (NP-BSA)-, C3a-induced β-hexosaminidase (β-Hex) release. MRS2690 disodium can be used for ischemic heart disease.
    MRS2690 disodium
Cat. No. Product Name / Synonyms Application Reactivity
P2Y Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.